Cullinan Therapeutics, Inc. (CGEM) Institutional Ownership

Ownership Summary

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) currently has 4 active institutional owners and shareholders as of today (December 2025), that have filed 13F forms with the Securities Exchange Commission (SEC).

• The percentage of Cullinan Therapeutics owned by institutions changed from 91.5% in September 2025 to 0.3% in December 2025, marking a slight down trend.
• In percentage terms, this reflects as a holdings change of -7.16% quarter on quarter, and a decrease of 97.30% year over year.
• Among the 4 institutional holders of Cullinan Therapeutics, 2 added to their stakes while 1 trimmed their positions and 1 held steady.
• The aggregate institutional position in Cullinan Therapeutics now stands at 175.39K shares as of December 2025, after investors decreased their holdings (down by 13.54K shares quarter on quarter which is down 65.49Mn shares year over year).
• Assenagon Asset Management S.A. continues to be the largest institutional holder of Cullinan Therapeutics as of December 31, 2025, with a position of 158.75K shares, representing 0.24% of the company's outstanding stock.
• Among the most significant buyers of Cullinan Therapeutics during December 2025 were SG Americas Securities, LLC (5.17K), GAMMA Investing LLC (232).
• Leading sellers of Cullinan Therapeutics stock in December 2025 included Assenagon Asset Management S.A. (18.93K).
• The top 4 institutional holders of Cullinan Therapeutics for the quarter ending December 2025 included Assenagon Asset Management S.A. (158.75K), SG Americas Securities, LLC (15.63K), GAMMA Investing LLC (980), MassMutual Private Wealth & Trust, FSB (27).